A Decade of Drug Development through Phase-1 Trials; Systematic Review of Literature for Novel Drugs and Targets in Multiple Myeloma

Introduction:Multiple Myeloma (MM) remains an incurable malignancy but response rates are reaching 90% with induction chemotherapy. Despite improved therapy, majority of the patients still face relapse and drug resistance (Korteum KM et al, 2014). There has been significant advancement in drug development for MM with the introduction of many new classes of drugs such as proteasome inhibitors, Immunomodulatory agents, histone deacetylase (HDAC) inhibitors, surface molecule targeting antibodies, intracellular transduction inhibitors and chimeric antigen T cells (CAR-T). The purpose of our study is to systematically summarize the drugs and targets tested through phase I during the last 10 years and their potential mechanisms of actions (MOA).